Patient satisfaction with glaucoma treatment has been poorly studied to date. Because glaucoma is a chronic condition in which the therapeutic response is dependent on adherence to treatment, patient acceptability is an important factor in achieving satisfactory outcomes. This multicenter, international (Belgium, the Netherlands, and Spain), epidemiological convenience sample survey among patie...

PURPOSE To examine the differences between Goldmann Applanation Tonometry (GAT) and Dynamic Contour Tonometry (DCT) associated with latanoprost use. METHODS Twenty-four eyes (of 24 patients) treated with latanoprost monotherapy (latanoprost group, LG), 11 eyes (of 11 patients) not receiving prostaglandin analogs (nonlatanoprost group, NLG), and 20 eyes of 20 nonglaucomatous patients (control ...

BACKGROUND To evaluate the efficacy and safety of latanoprost compared with timolol in the treatment of Asian patients with chronic angle-closure glaucoma (CACG). METHODS Relevant trials were identified through systematic searches of Medline, EMBASE, PubMed, Cochrane Library, Google Scholar and several Chinese databases. The main outcome measures included absolute and relative reduction of in...

OBJECTIVE Detrimental effects of the preserved prostaglandin analogs (PGAs) have been thoroughly documented in the published literature. The current work studied two preservative-free (PF) prostaglandin eye drops: PF tafluprost and PF latanoprost. The aim of the study was to compare these two PF formulations in vitro for viability of the human corneal epithelial (HCE-T) cells and in vivo for oc...

OBJECTIVE To compare the circadian intraocular pressure (IOP) reductions induced by latanoprost, brimonidine tartrate, and a fixed combination of timolol maleate and dorzolamide hydrochloride in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT). METHODS In this crossover study, 10 patients with POAG and 10 with OHT were treated with latanoprost once a day, brimonid...

AIM To investigate the effect on intraocular pressure (IOP) and aqueous flare of topical applications of latanoprost and dipivefrin alone or combined. METHODS 22 patients with open angle glaucoma or ocular hypertension were included in a 4 week open label study. Median age was 68 years (range 50-79). They were allocated to either 2 weeks' treatment with once daily evening administration of la...

BACKGROUND To compare the daily costs of 3 prostaglandin analogues (bimatoprost, latanoprost, travoprost), alone, and associated with timolol in 4 European countries (Denmark, Finland, Germany, and Sweden). METHODS Six glaucoma products were sampled by buying 5 bottles from 1 suburban pharmacy in each of the 4 countries. Drops were weighed by a single operator at 1 site according to standardi...

PURPOSE To determine whether latanoprost lowers IOP in prostaglandin FP receptor knockout mice. METHODS Mean IOP difference between treated and untreated fellow eyes was measured on three separate occasions, 2 hours after a 200-ng dose of latanoprost to the right eye of homozygous (n = 9) and heterozygous (n = 15) FP knockout mice. C57BL/6 (n = 10) and NIH Swiss white mice (n = 17), which hav...

The purpose of this study was to evaluate the effects of a combination of latanoprost and pilocarpine onthe intraocular pressure in experimentally glaucomatous rabbits. Ocular hypertension was induced in 11conscious rabbits by the oral administration of tap water (70 mL/kg) via an orogastric tube. The study wasconducted in three therapeutic groups to test the effects of latanoprost (group L), p...

PURPOSE With use of the Wong-Kilbourne derivative Chang conjunctival cell line, this study compared in vitro the ocular toxicity of three topical intraocular pressure (IOP)-lowering agents: travoprost 0.004% containing 0.015% benzalkonium chloride (BAK), travoprost Z 0.004%, a new formulation without BAK, and latanoprost 0.005% containing 0.02% BAK. METHODS Neutral red, Alamar blue, YOPRO-1, ...